Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 8 min read

  1. French DP, Astley S, Brentnall AR, Cuzick J, Dobrashian R, Duffy SW, et al. What are the benefits and harms of risk stratified screening as part of the NHS Breast Screening Programme? Study protocol for a multi-site non-randomised comparison of BC-Predict versus usual screening (NCT04359420). BMC Cancer 2020;20:570. 10.1186/s12885-020-07054-232552763
  2. Evans DG, McWilliams L, Astley S, Brentnall AR, Cuzick J, Dobrashian R, et al. Quantifying the effects of risk stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420). Br J Cancer 2023;128:2063–71. 10.1038/s41416-023-02250-w37005486
  3. French DP, McWilliams L, Bowers S, Woof V, Harrison F, Ruane H, et al. Psychological impact of risk stratified screening as part of the NHS Breast Screening Programme: multi-site non-randomised comparison of BC-Predict versus usual screening (NCT04359420). Br J Cancer 2023;128:1548–58. 10.1038/s41416-023-02156-736774447
  4. Cancer Research UK. Breast Cancer Diagnosis and Treatment Statistics. 2022. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Zero (accessed 25 May 2022).
  5. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778–86. 10.1016/S0140-6736(12)61611-023117178
  6. Evans DG, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, et al. Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: a new paradigm for cancer prevention. Cancer Prev Res 2012;5:943–51. 10.1158/1940-6207.CAPR-11-0458
  7. National Institute of Health and Care Excellence. Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. Clinical Guideline 164. London: National Institute for Health and Care Excellence; 2013.
  8. Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, et al. Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res 2014;7:993–1001. 10.1158/1940-6207.CAPR-14-0037
  9. Evans DG, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, et al. Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer 2016;114:1045–52. 10.1038/bjc.2016.5627022688
  10. Evans DG, Astley SM, Stavrinos P, Harkness E, Donnelly LS, Dawe S, et al. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants Appl Res 2016;4:1–210. 10.3310/pgfar04110
  11. Pashayan N, Antoniou A, Ivanus U, Esserman L, Easton D, French DP, et al. (2020). Personalised early detection and prevention of breast cancer: ENVISION Consensus Statement. Nat Rev Clin Oncol 2020;17:687–705. 10.1038/s41571-020-0388-932555420
  12. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ 2021;374:n2061. 10.1136/bmj.n206134593508
  13. Gorman LS, Ruane H, Woof V, Southworth J, Ulph F, Evans DG, et al. The co-development of personalized 10-year breast cancer risk communications: a ‘think aloud’ study. BMC Cancer 2022;22:1264. 10.1186/s12885-022-10347-336471302
  14. Forbes LJL, Ramirez AJ; Expert Group on Information about Breast Screening. The Expert group on Information about Breast Screening. Offering informed choice about breast screening. J Med Screen 2014;21:194–200. 10.1177/096914131455535025312639
  15. Ramirez A, Forbes L. Approach to Developing Information about NHS Cancer Screening Programmes. London: King’s Health Partners; 2012.
  16. Spiegelhalter DJ, Short I, Pearson M. Visualizing uncertainty about the future. Science 2011;333:1393–400. 10.1126/science.119118121903802
  17. French DP, Cooke R, McLean N, Williams M, Sutton S. What do people think about when they answer theory of planned behaviour questionnaires? A ‘think aloud’ study. J Health Psychol 2007;12:672–87. 10.1177/135910530707817417584818
  18. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101. 10.1191/1478088706qp063oa
  19. Woof VG, Ruane H, Ulph F, French DP, Qureshi N, Khan N, et al. Engagement barriers and service inequities in the NHS breast screening Programme: views from British-Pakistani women. J Med Screen 2020;27:130–7. 10.1177/096914131988740531791172
  20. Woof VG, Ruane H, Ulph F, French DP, Qureshi N, Khan N, et al. The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women. BMC Cancer 2020;20:1–9. 10.1186/s12885-020-06959-2
  21. Office for National Statistics. KS201EW – 2011 Census: Ethnic Group, Local Authority in England and Wales. 2012. URL: www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/2011censuskeystatisticsforlocalauthoritiesinenglandandwales (accessed 25 October 2019).
  22. NHS Digital. Breast Screening Programme, England – 2016–17 (PAS). 2018. URL: https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme/breast-screening-programme-england-2016-17 (accessed 25 October 2019).
  23. French DP, Woof VG, Ruane H, Evans DG, Ulph F, Donnelly LS. The feasibility of implementing risk stratification into a national breast cancer screening programme: perspectives of healthcare personnel responsible for delivery. BMC Womens Health 2022;22:142. 10.1186/s12905-022-01730-035501791
  24. Weinstein ND. What does it mean to understand a risk? Evaluating risk comprehension. J Natl Cancer I Monogr 1999;25:15–20. 10.1093/oxfordjournals.jncimonographs.a024192
  25. Marteau TM, Becker H. The development of a six-item short-form of the state scale of the Spielberger state-trait anxiety inventory (STAI). Br J Clin Psychol 1992;31:301–06. 10.1111/j.2044-8260.1992.tb00997.x1393159
  26. Spielberger CD, Gorsuch RL, Luschen RE. State Trait Anxiety Inventory Manual. Palo Alto, CA: Consulting Psychologists Press; 1970.
  27. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. Health Psychol 1991;10:259–67. 10.1037//0278-6133.10.4.2591915212
  28. Department for Communities and Local Government. The English Indices of Deprivation. 2019. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/835115/IoD2019_Statistical_Release.pdf (accessed 11 March 2022).
  29. McWilliams L, Ruane H, Ulph F, Woof VG, Harrison F, Evans DG, French DP. What do women think about having received their breast cancer risk as part of a risk stratified NHS Breast Screening Programme? A qualitative study. Br J Cancer 2023;129:356–65. 10.1038/s41416-023-02268-037225893
  30. Hawkins R, McWilliams L, Ulph F, Evans DG, French DP. Healthcare professionals’ views following implementation of risk stratification into a national breast cancer screening programme. BMC Cancer 2023;22:1058. 10.1186/s12885-022-10134-0
  31. UNICANCER. My Personalised Breast Screening (MyPeBS). Clinicaltrials.gov; 2018. URL: https://clinicaltrials.gov/ct2/show/NCT03672331 (accessed 25 May 2022).
  32. French DP, McWilliams L, Howell A, Evans G. Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study. Breast 2022;64:47–9.35569186
  33. Woof VG, McWilliams L, Donnelly LS, Howell A, Evans DG, Maxwell A, French DP. Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: views from healthcare professionals who are delivering risk-stratified screening. Women’s Health 2021;17:1009746. 10.1177/17455065211009746.
  34. Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer 2014;110:1681–87. 10.1038/bjc.2014.10924594998
  35. Howell A, Gandhi A, Howell S, Wilson M, Maxwell A, Astley S, et al. Long-term evaluation of women referred to a breast cancer family history clinic (Manchester UK 1987–2020). Cancers 2020;12:3697. 10.3390/cancers1212369733317064
  36. Wright SJ, Eden M, Ruane H, Byers H, Evans DG, Harvie M, et al. Estimating the cost of 3 risk prediction strategies for potential use in the United Kingdom National Breast Screening Programme. MDM Policy Pract 2023;8:171363. 10.1177/23814683231171363.
  37. Gray E, Donten A, Karssemeijer N, van Gils C, Evans DG, Astley S, Payne K. Evaluation of a stratified National Breast Screening Program in the United Kingdom: an early model-based cost-effectiveness analysis. Value Health 2017;20:1100–9. 10.1016/j.jval.2017.04.01228964442
  38. Frick KD. Microcosting quantity data collection methods. Med Care 2009;47:S76–81. 10.1097/MLR.0B013E31819BC06419536026
  39. Jani M, Gavan S, Chinoy H, Dixon WG, Harrison B, Moran A, et al. A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology 2016;55:2131–7. 10.1093/RHEUMATOLOGY/KEW29227576368
  40. Wright SJ, Gray E, Rogers G, Hainsworth R, Donten A, Payne K. Validation of a decision-analytic model for the cost-effectiveness of a risk-stratified National Breast Screening Programme in the United Kingdom. medRxiv 2022. 10.1101/2022.12.05.22283099
  41. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217–27. 10.1002/(sici)1099-1050(199705)6:3%3C217::aid-hec267%3E3.0.co;2-w9226140
  42. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997;2:26–30. 10.1177/13558196970020010710180650
  43. Tappenden P, Chilcott JB. Avoiding and identifying errors and other threats to the credibility of health economic models. PharmacoEcon 2014;32:967–79. 10.1007/S40273-014-0186-2
  44. Emerson J, Bacon R, Kent A, Neumann PJ, Cohen JT. Publication of decision model source code: attitudes of health economics authors. PharmacoEcon 2019;37:1409–10. 10.1007/S40273-019-00796-3
  45. Jansen JP, Incerti D, Linthicum MT. Developing open-source models for the US health system: practical experiences and challenges to date with the open-source value project. PharmacoEcon 2019;37:1313–20. 10.1007/S40273-019-00827-Z
  46. Büyükkaramikli NC, Rutten-van Mölken MP, Severens JL, Al M. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. PharmacoEcon 2019;37:1391–408. 10.1007/s40273-019-00844-y
  47. Hammerschmidt T, Goertz A, Wagenpfeil S, Neiss A, Wutzler P, Banz K. Validation of health economic models: the example of EVITA. Value Health 2003;6:551–9. 10.1046/J.1524-4733.2003.65241.X14627061
  48. Haji Ali Afzali H, Gray J, Karnon J. Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases. Appl Heal Econ Heal Policy 2013;11:85–93. 10.1007/S40258-013-0012-6
  49. Ramer SL. Site-ation pearl growing: methods and librarianship history and theory. J Med Libr Assoc 2005;93:397–400. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC1175807/ (accessed 9 October 2025).16059431
  50. Schlosser RW, Wendt O, Bhavnani S, Nail-Chiwetalu B. Use of information-seeking strategies for developing systematic reviews and engaging in evidence-based practice: the application of traditional and comprehensive pearl growing. a review. Int J Lang Commun Disord 2006;41:567–82. 10.1080/1368282060074219017050471
  51. Hinde S, Spackman E. Bidirectional citation searching to completion: an exploration of literature searching methods. PharmacoEcon 2015;33:5–11. 10.1007/s40273-014-0205-3
  52. Karnon J, Stahl S, Brennan A, Caro JJ, Mar J, Möller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4. Value Health 2012;15:821–27. 10.1016/J.JVAL.2012.04.01322999131
  53. McWilliams L, Evans DG, Payne K, Harrison F, Howell A, Howell SJ, French DP; Breast Screening Risk-Stratification Agenda Setting Group. Implementing risk stratified breast screening in England: an agenda setting meeting. Cancers 2022;14:4636. 10.3390/cancers1419463636230559
  54. Anderson A, Visintin C, Antoniou A, Pashayan N, Gilbert FJ, Hackshaw A, et al. Risk stratification in breast screening workshop. BMC Proc 2024;18:22. URL: https://link.springer.com/epdf/10.1186/s12919-024-00306-0 (accessed 25 October 2024).39444025
  55. McWilliams L, Woof VG, Donnelly LS, Howell A, Evans DG, French DP. Extending screening intervals for women at low risk of breast cancer: do they find it acceptable? BMC Cancer 2021;21:637. 10.1186/s12885-021-08347-w34051753
  56. McWilliams L, Woof VG, Donnelly LS, Howell A, Evans DG, French DP. Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders’ views on a low-risk breast screening pathway. BMC Cancer 2020;20:680. 10.1186/s12885-020-07158-932698780
  57. Taylor G, McWilliams L, Woof VG, Howell A, Evans DG, French DP. What are the views of key stakeholders on extending the breast screening interval for low-risk women? Health Expect 2022;25:3287–96. 10.1111/hex.1363736305519
← SynopsisAdditional information →

Attribution. David P French; Lorna McWilliams; Katherine Payne; Victoria G Woof; Fiona Harrison; Andrew Jerrison et al. (2025). The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme. National Institute for Health and Care Research. Copyright © 2025 French et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK619493. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support